Metamizole-containing medicinal products: risk of agranulocytosis - referral
2024.06.14
Active substance: metamizole
14.06.2024 – start of procedure
Review will look into risk of agranulocytosis, a sudden drop in white blood cells that can lead to serious infections, and measures to minimise it
EMA has started a review of medicines containing the painkiller metamizole following concerns that the measures in place to minimise the known risk of agranulocytosis may not be effective enough.
Further information
For details on the procedure please click on the following link to the homepage of the European Medicines Agency (EMA):